Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426992 | 0.78 | CYP1A2 (0.44) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL2401081 | 0.78 | CYP1A2 (0.44) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL14769176 | 0.78 | ALDH1A1 (0.43) | CYP1A2ALDH1A1 | |
| SCHEMBL14769163 | 0.76 | LIPG (0.38) | — | |
| SCHEMBL9005990 | 0.75 | CYP1A2 (0.46) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1 | |
| SCHEMBL12723090 | 0.72 | CYP1A2 (0.49) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL14769243 | 0.70 | CYP19A1 (0.41) | ALDH1A1HPGD | |
| SCHEMBL14769121 | 0.70 | PGK1 (0.60) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1 | |
| SCHEMBL14769251 | 0.69 | FDPS (0.43) | ALDH1A1HPGD | |
| SCHEMBL1585267 | 0.69 | CYP1A2 (0.45) | CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | CYP1A2 4027/4885GPBAR1 1179/4885CYSLTR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.